Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Frauke M. Schnorfeil"'
Autor:
Felix S. Lichtenegger, Maurine Rothe, Frauke M. Schnorfeil, Katrin Deiser, Christina Krupka, Christian Augsberger, Miriam Schlüter, Julia Neitz, Marion Subklewe
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Immune checkpoint inhibition has been shown to successfully reactivate endogenous T cell responses directed against tumor-associated antigens, resulting in significantly prolonged overall survival in patients with various tumor entities. For malignan
Externí odkaz:
https://doaj.org/article/e3b44104ed7d475bbd0fad0198a7ea17
Autor:
Stefanie Völk, Franziska S. Thaler, Marion Subklewe, Edgar Meinl, Stephan Winklmeier, Christoph Mahler, Tania Kümpfel, Reinhard Hohlfeld, Frauke M. Schnorfeil, Elisabeth Schuh, Ramona Gerhards, Michelle Biljecki, Anna L. Thaller
Publikováno v:
Annals of Neurology. 85:448-454
High levels of antibodies against glutamic acid decarboxylase (GAD) are observed in patients with different neurological disorders, but cells producing these autoantibodies are largely unexplored. We detect circulating GAD-reactive B cells in periphe
Autor:
Dolores J. Schendel, Christiane Geiger, Yngvar Fløisand, Dag Josefsen, Kai Pinkernell, Anna Tafuri, Gunnar Kvalheim, Frauke M. Schnorfeil, Iris Bigalke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background A Phase I/II dendritic cell (DC) vaccine trial was completed in 20 patients with acute myeloid leukemia (AML) in complete remission or CRi after chemotherapy who were ineligible for hematopoietic stem cell transplantation (NCT02405338). Th
Autor:
Paul Kerbs, Philipp A. Greif, Wolfgang Hiddemann, Michel Sadelain, Marion Subklewe, Tobias Herold, Fabiana Perna, Samuel H. Berman, Stephanie Schneider, Sascha Haubner, Christina Krupka, Thomas Köhnke, Christian Augsberger, Felix S. Lichtenegger, X. Liu, Karsten Spiekermann, Christian Schmidt, Klaus H. Metzeler, Frauke M. Schnorfeil
Publikováno v:
Leukemia
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that
Autor:
Frauke M. Schnorfeil, Kai Pinkernell, Yngvar Fløisand, Richard Addo, Dolores J. Schendel, Gunnar Kvalheim, Iris Bigalke, Silke Raffegerst, Dag Josefsen
Publikováno v:
Blood. 136:11-11
Patients with acute myeloid leukemia (AML), not eligible for allogeneic hematopoietic stem cell transplantation (AHSCT), have a significant risk of disease relapse and death due to a lack of long-term disease control. To investigate the possibility o
Autor:
Yngvar Fløisand, Dolores J. Schendel, Christiane Fingerhut, Judith Eckl, Iris Bigalke, Silke Raffegerst, Petra Prinz-Schulz, Dag Josefsen, Frauke M. Schnorfeil, Kai Pinkernell, Gunnar Kvalheim, Anna Tafuri
Publikováno v:
Blood. 134:3923-3923
Acute myeloid leukemia (AML) is a lethal hematological malignancy characterized by high rates of relapse (50%). Studies of immune responses in AML patients led to identification of two leukemia-associated antigens (Wilms' tumor protein 1 (WT1) and pr
Autor:
Felix S, Lichtenegger, Maurine, Rothe, Frauke M, Schnorfeil, Katrin, Deiser, Christina, Krupka, Christian, Augsberger, Miriam, Schlüter, Julia, Neitz, Marion, Subklewe
Publikováno v:
Frontiers in Immunology
Immune checkpoint inhibition has been shown to successfully reactivate endogenous T cell responses directed against tumor-associated antigens, resulting in significantly prolonged overall survival in patients with various tumor entities. For malignan
Autor:
Thomas Köhnke, Marion Subklewe, Cristina Sauerland, Frauke M. Schnorfeil, Wolfgang Hiddemann, Nikola P. Konstandin, Veit Bücklein, Annika Dufour, Karsten Spiekermann, Klaus H. Metzeler
Publikováno v:
Blood. 132:2753-2753
The prognosis of patients with AML is determined by a multitude of recurrent genetic alterations, and treatment algorithms heavily rely on risk stratification by genetic characterization of the disease at the time of diagnosis. However, this a priori
Autor:
Iris Bigalke, Thomas Köhnke, Torben Altmann, Christian Augsberger, Marion Subklewe, Frauke M. Schnorfeil, Christina Krupka, Wolfgang Hiddemann, Maurine Rothe, Monika Brüggemann, Andreas Moosmann, Gunnar Kvalheim, Georg Wittmann, Mirjam H.M. Heemskerk, Felix S. Lichtenegger, Veit Bücklein, Katrin Deiser, Beate Wagner
Publikováno v:
Blood. 128:764-764
Postremission therapy is critical for successful elimination of minimal residual disease (MRD) in acute myeloid leukemia (AML). Innovative treatment options are needed for patients that are not eligible for allogeneic stem cell transplantation. As th
Publikováno v:
Immunotherapy. 5(1)
The prognosis of acute myeloid leukemia, particularly when associated with adverse chromosomal or molecular aberrations, is poor due to a high relapse rate after induction chemotherapy. Postremission therapy for elimination of minimal residual diseas